First mRNA vaccine for chlamydia enters human testing
A study testing a new mRNA vaccine to prevent chlamydia infection in young adults. It's currently recruiting 1,560 participants aged 18-29.
Read lead report →Weekly edition
The 10 most notable cure or vaccine studies from the last week.
A study testing a new mRNA vaccine to prevent chlamydia infection in young adults. It's currently recruiting 1,560 participants aged 18-29.
Read lead report →A Phase 2 trial testing a new cholera vaccine's safety and immune response in 390 adults and children living in areas where cholera is common.
Read report →Study testing if an extra dose of the shingles vaccine improves protection for kidney transplant patients. Enrolling 132 participants.
Read report →A study testing a new COVID-19 booster vaccine made from a modified animal virus in 96 healthy adults to check its safety and immune response.
Read report →Phase 3 trial testing a freeze-dried rabies vaccine in 3,000 people. Compares different shot schedules to see which works best to build immunity safely.
Read report →Phase 3 trial testing a new meningitis vaccine in 880 healthy infants aged 3-5 months. Compares immune response and safety against an existing vaccine.
Read report →A Phase 1 study testing new vaccine formulations for RSV and H5N1 bird flu in healthy adults. It will check safety and immune response.
Read report →Phase 1 study testing safety of a new RSV vaccine in healthy women aged 18-49. Looking at immune response and side effects.
Read report →